AI Article Synopsis
- The study aimed to compare survival rates and risk factors between two subtypes of ampullary adenocarcinoma (intestinal and pancreatobiliary) using data from 184 patients who had operations between 2007 and 2018.
- Results showed that the pancreatobiliary subtype had worse outcomes, including larger tumors, higher rates of jaundice and perineural invasion, and more advanced disease stages compared to the intestinal subtype.
- Both subtypes did not benefit from adjuvant chemotherapy, and the pancreatobiliary subtype had higher recurrence rates and poorer overall survival compared to the intestinal subtype.
Article Abstract
Objectives: This study aimed to compare the intestinal and pancreatobiliary subtypes of ampullary adenocarcinoma in a large patient group due to limited data on survival and risk factors.
Methods: A retrospective analysis of the clinical and pathological findings and the survival of 184 patients with ampullary adenocarcinoma who underwent curative operation between 2007 and 2018 was performed.
Results: Pancreatobiliary subtype had a higher prevalence of jaundice before operation than the intestinal subtype (p < 0.05). Pancreatobiliary subtype had a larger tumor size (> 2 mm) (p < 0.01) and poorer differentiation (p < 0.05) than the intestinal subtype. Perineural invasion more frequently occurred in pancreatobiliary subtype than the intestinal subtype (p < 0.01) and pancreatobiliary subtype had a higher prevalence of positive dissected lymph nodes (p < 0.05) with an advanced disease stage (p < 0.01) than the intestinal subtype. Patients of the pancreatobiliary subtype had poorer disease-free and overall survival than patients of the intestinal subtype. No survival benefit of adjuvant chemotherapy was found in either patients of the intestinal subtype or pancreatobiliary subtype. No significant difference was found in any subtypes regarding the recurrent regions.
Conclusions: Pancreatobiliary subtype exhibited a higher recurrence rate and a poorer overall survival rate with more unfavorable pathological characteristics than the intestinal subtype.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.24875/CIRU.23000021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology and survival analysis according to the histologic subtype of pancreatic cancer: a population-based cohort study.
Ann Surg Treat Res
January 2025
Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.
Purpose: This study investigated epidemiologic features of patients with pancreatic cancer in Korea, according to the histologic subtypes.
Methods: The Korea Central Cancer Registry data on patients with pancreatic cancer from 1999 to 2019 were reviewed. The 101,446 patients with pancreatic cancer (C25 based on the International Classification of Diseases, 10th revision) were allocated according to the following morphological codes: A, endocrine; B, carcinoma excluding cystic and mucinous; C, cystic or mucinous; D, acinar cell; and E, sarcoma and soft tissue tumor.
Multimodal single cell-resolved spatial proteomics reveal pancreatic tumor heterogeneity.
Nat Commun
November 2024
State Key Laboratory of Medical Proteomics and Shenzhen Key Laboratory of Functional Proteomics, Department of Chemistry and Research Center for Chemical Biology and Omics Analysis, School of Science and Guangming Advanced Research Institute, Southern University of Science and Technology, Shenzhen, China.
Despite the advances in antibody-guided cell typing and mass spectrometry-based proteomics, their integration is hindered by challenges for processing rare cells in the heterogeneous tissue context. Here, we introduce Spatial and Cell-type Proteomics (SCPro), which combines multiplexed imaging and flow cytometry with ion exchange-based protein aggregation capture technology to characterize spatial proteome heterogeneity with single-cell resolution. The SCPro is employed to explore the pancreatic tumor microenvironment and reveals the spatial alternations of over 5000 proteins by automatically dissecting up to 100 single cells guided by multi-color imaging of centimeter-scale formalin-fixed, paraffin-embedded tissue slide.
View Article and Find Full Text PDFA simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort.
ESMO Open
December 2024
Institut du Cancer Paris CARPEM, APHP, Hepatogastroenterology and GI Oncology Department, APHP Centre-Université Paris Cité, Hôpital Européen G. Pompidou, Paris, France. Electronic address:
Background: Ampullary carcinoma (AC) is a rare and severe gastrointestinal cancer with a disease recurrence rate of around 40% after curative-intent surgery and for which the main prognostic factors and adjuvant treatment decision remain a matter of debate.
Patients And Methods: The FFCD-AC cohort is a French nationwide prospective cohort, which included patients with non-metastatic resected AC. The primary objective of this study was to describe prognostic factors associated with disease-free survival (DFS) and overall survival (OS) after pancreaticoduodenectomy (PD) so as to propose a user-friendly score to better estimate the risk of recurrence.
Article Synopsis
- The ampulla of Vater is a critical site in the duodenal wall where pancreatic and biliary ducts meet, often linked to tumors known as ampullary adenocarcinomas.
- A study analyzed 188 cases to compare intra-ampullary and periampullary carcinomas in terms of pathology and survival, revealing that most tumors were found in males around 55 years old, with a predilection for the pancreatobiliary subtype.
- Results indicated that intra-ampullary carcinomas had worse outcomes, showing more extensive invasion and lower median survival rates (46 months) compared to periampullary carcinomas (53.5 months).
Genome-Derived Ampullary Adenocarcinoma Classifier and Postresection Prognostication.
JAMA Surg
December 2024
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Article Synopsis
- Ampullary adenocarcinoma (AA) shows clinical and genetic diversity, and a new genomic classifier may improve patient classification beyond traditional methods, but it needs validation before being widely used.
- A study involving 192 patients with AA assessed the accuracy of this genomic classifier against standard histology to see if it could predict survival outcomes.
- Results indicated a 55% agreement between genomic and histological classifications; however, while histological subtypes did not predict survival, the genomic scores did correlate with survival probabilities, suggesting the genomic approach might be more effective.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!